{"id":"high-dose-melphalan","safety":{"commonSideEffects":[{"rate":"90+","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"40-60","effect":"Mucositis"},{"rate":"50-70","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"20-40","effect":"Infection"},{"rate":"5-10","effect":"Secondary malignancy"},{"rate":null,"effect":"Infertility"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Melphalan is a nitrogen mustard alkylating agent that covalently binds to DNA, creating interstrand crosslinks that prevent DNA replication and transcription, leading to apoptosis. At high doses, it achieves greater tumor cell kill but requires autologous stem cell transplantation to rescue bone marrow function. This approach is particularly effective in multiple myeloma and other chemotherapy-sensitive hematologic cancers.","oneSentence":"High-dose melphalan is an alkylating agent that crosslinks DNA strands, causing cell death, and is used in high doses followed by stem cell rescue to treat hematologic malignancies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:50.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (with autologous stem cell transplantation)"},{"name":"Light chain amyloidosis"},{"name":"Waldenström macroglobulinemia"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT03494569","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-07-06","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia","enrollment":36},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT06607458","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2025-08-05","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT06875128","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2026-01-29","conditions":"Metastatic Breast Cancer in the Liver","enrollment":90},{"nctId":"NCT04802356","phase":"PHASE2","title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-04-07","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":"Multiple Myeloma","enrollment":306},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT00003042","phase":"PHASE2","title":"Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1997-05-30","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT03617731","phase":"PHASE3","title":"Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2018-10-18","conditions":"Multiple Myeloma","enrollment":662},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT01208766","phase":"PHASE3","title":"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2011-01","conditions":"Multiple Myeloma","enrollment":1503},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT05130827","phase":"PHASE2","title":"Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-21","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT05115630","phase":"PHASE2","title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-08","conditions":"Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT00692939","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplantation for Crohn's Disease","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2012-06-26","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT01794572","phase":"NA","title":"Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2013-04-09","conditions":"Multiple Myeloma in Relapse","enrollment":13},{"nctId":"NCT01840566","phase":"PHASE1","title":"High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":17},{"nctId":"NCT02570542","phase":"PHASE2","title":"Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-10","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":59},{"nctId":"NCT03011528","phase":"PHASE2","title":"First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2016-12","conditions":"Ewing Sarcoma Family of Tumors","enrollment":45},{"nctId":"NCT01885689","phase":"PHASE2","title":"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-02-10","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission","enrollment":72},{"nctId":"NCT03259503","phase":"PHASE1","title":"Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-13","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":50},{"nctId":"NCT01526096","phase":"PHASE1","title":"Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-07-12","conditions":"Myeloma","enrollment":30},{"nctId":"NCT03602235","phase":"PHASE1","title":"High Dose Ascorbic Acid for Plasma Cell Disorders","status":"COMPLETED","sponsor":"Christopher Strouse","startDate":"2019-03-05","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT02605421","phase":"PHASE2","title":"Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-06","conditions":"Neuroblastoma","enrollment":12},{"nctId":"NCT04678401","phase":"PHASE1","title":"IS-free Treg HaploHCT","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-12","conditions":"Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute","enrollment":30},{"nctId":"NCT02508038","phase":"PHASE1","title":"Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2016-02-12","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma","enrollment":22},{"nctId":"NCT02909036","phase":"PHASE1","title":"Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-09","conditions":"Multiple Myeloma, Amyloidosis","enrollment":46},{"nctId":"NCT01908777","phase":"PHASE2","title":"A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-07-16","conditions":"T Cell Non-Hodgkin Lymphoma","enrollment":47},{"nctId":"NCT07199296","phase":"PHASE2","title":"Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-07-01","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":45},{"nctId":"NCT04862676","phase":"EARLY_PHASE1","title":"Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2022-04-22","conditions":"Myeloma","enrollment":29},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT06793449","phase":"PHASE2","title":"BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-02-05","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT02278796","phase":"PHASE2","title":"A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":108},{"nctId":"NCT06287944","phase":"PHASE1","title":"225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-07-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":15},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT07059741","phase":"NA","title":"Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-10","conditions":"Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)","enrollment":20},{"nctId":"NCT05139004","phase":"PHASE1","title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-19","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":7},{"nctId":"NCT03713580","phase":"PHASE1","title":"Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Non-hodgkin Lymphoma","enrollment":25},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT06313502","phase":"PHASE1","title":"High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders","status":"RECRUITING","sponsor":"University of Arkansas","startDate":"2024-07-19","conditions":"Plasma Cell Disorder","enrollment":18},{"nctId":"NCT00112827","phase":"PHASE1, PHASE2","title":"Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2004-11","conditions":"Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma","enrollment":54},{"nctId":"NCT04483206","phase":"PHASE1","title":"Personalized Autologous Transplant for Multiple Myeloma","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-05-20","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT01054196","phase":"PHASE1, PHASE2","title":"Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2010-08","conditions":"Multiple Myeloma","enrollment":52},{"nctId":"NCT04690192","phase":"PHASE1, PHASE2","title":"CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-01-01","conditions":"Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT01729091","phase":"PHASE2","title":"Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-06-10","conditions":"Plasma Cell Leukemia, Plasma Cell Myeloma","enrollment":72},{"nctId":"NCT03556332","phase":"PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-02","conditions":"Multiple Myeloma","enrollment":41},{"nctId":"NCT06125483","phase":"NA","title":"TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-11-01","conditions":"Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation","enrollment":38},{"nctId":"NCT06913192","phase":"PHASE1","title":"Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2025-04-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT03187210","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas","status":"SUSPENDED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-09-01","conditions":"Lymphoma","enrollment":20},{"nctId":"NCT00638898","phase":"PHASE1","title":"Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-02-26","conditions":"Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma","enrollment":25},{"nctId":"NCT01758328","phase":"PHASE1","title":"Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT02506959","phase":"PHASE2","title":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma","enrollment":83},{"nctId":"NCT03187223","phase":"PHASE2","title":"Bendamustine and Melphalan in Myeloma","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-07-20","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT06245629","phase":"","title":"Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-11-24","conditions":"Myeloma Multiple","enrollment":100},{"nctId":"NCT06588413","phase":"PHASE3","title":"Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-09-17","conditions":"Multiple Myeloma, Autologous Stem Cell Transplantation","enrollment":172},{"nctId":"NCT04099901","phase":"PHASE2","title":"Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-11-04","conditions":"Multiple Myeloma","enrollment":88},{"nctId":"NCT03233776","phase":"PHASE2","title":"Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2017-08-21","conditions":"Multiple Myeloma","enrollment":9},{"nctId":"NCT02043847","phase":"PHASE1","title":"TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2014-01-14","conditions":"Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment","enrollment":12},{"nctId":"NCT01091831","phase":"PHASE3","title":"Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2009-07","conditions":"Multiple Myeloma","enrollment":389},{"nctId":"NCT02939287","phase":"PHASE3","title":"Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2017-09-23","conditions":"Nausea, Vomiting","enrollment":52},{"nctId":"NCT06602323","phase":"PHASE2","title":"TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-01","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT00936936","phase":"PHASE2","title":"High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06-02","conditions":"Testicular Cancer","enrollment":64},{"nctId":"NCT00551928","phase":"PHASE3","title":"Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2007-06","conditions":"Multiple Myeloma, Newly Diagnosed Patients","enrollment":402},{"nctId":"NCT02295722","phase":"PHASE1, PHASE2","title":"GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2015-04","conditions":"Hodgkin's Lymphoma - Relapsed/Refractory, Non-Hodgkin's Lymphoma - Aggressive, Follicular Lymphoma","enrollment":100},{"nctId":"NCT06463717","phase":"","title":"Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-12-01","conditions":"Multiple Myeloma, Minimal Residual Disease","enrollment":210},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT06425276","phase":"PHASE4","title":"Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation","status":"COMPLETED","sponsor":"CASI Pharmaceuticals (China) Co., Ltd.","startDate":"2020-07-24","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT02728102","phase":"PHASE2","title":"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2016-07","conditions":"Multiple Myeloma","enrollment":203},{"nctId":"NCT03217812","phase":"PHASE3","title":"A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-23","conditions":"Multiple Myeloma","enrollment":220},{"nctId":"NCT05013437","phase":"EARLY_PHASE1","title":"Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma","status":"WITHDRAWN","sponsor":"Koen van Besien","startDate":"2023-09","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02700841","phase":"PHASE2","title":"Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2020-01-09","conditions":"Plasma Cell Myeloma","enrollment":8},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT01526603","phase":"NA","title":"High Dose Chemotherapy and Autologous Transplant for Neuroblastoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-03-28","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT01904136","phase":"PHASE1, PHASE2","title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-04-22","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations","enrollment":54},{"nctId":"NCT03128359","phase":"PHASE2","title":"High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2017-05-30","conditions":"Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":38},{"nctId":"NCT00968760","phase":"PHASE1","title":"CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06-20","conditions":"Lymphoma, B-cell Lymphoma","enrollment":34},{"nctId":"NCT06149390","phase":"","title":"ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2014-01-01","conditions":"T-cell Lymphoma Adults","enrollment":347},{"nctId":"NCT00080886","phase":"PHASE2","title":"Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2002-05-08","conditions":"Lymphoma","enrollment":68},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT00572013","phase":"PHASE1, PHASE2","title":"Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1998-05-12","conditions":"Lymphoma","enrollment":32},{"nctId":"NCT00007852","phase":"PHASE2","title":"Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-09-01","conditions":"Lymphoma","enrollment":44},{"nctId":"NCT03276481","phase":"","title":"Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-28","conditions":"Multiple Myeloma","enrollment":47},{"nctId":"NCT05922384","phase":"NA","title":"Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma","status":"RECRUITING","sponsor":"Affiliated Hospital of Guangdong Medical University","startDate":"2023-07-05","conditions":"HIV Infections, Lymphoma","enrollment":3},{"nctId":"NCT00003353","phase":"PHASE2","title":"High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1998-11-16","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00052884","phase":"PHASE1","title":"Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-01-22","conditions":"Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":8},{"nctId":"NCT00641030","phase":"PHASE1","title":"Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-07","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":20},{"nctId":"NCT00074269","phase":"PHASE2","title":"Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2003-07","conditions":"Breast Cancer","enrollment":5},{"nctId":"NCT05855122","phase":"PHASE4","title":"Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-04-17","conditions":"Multiple Myeloma","enrollment":48},{"nctId":"NCT02416206","phase":"PHASE2","title":"High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2015-04-27","conditions":"Multiple Myeloma","enrollment":65},{"nctId":"NCT03234335","phase":"","title":"High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-04-10","conditions":"Multiple Myeloma, Renal Failure","enrollment":50},{"nctId":"NCT00253435","phase":"PHASE2","title":"N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2005-09","conditions":"Neuroblastoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"THROMBOCYTOPENIA"},{"count":2,"reaction":"HYPERTENSION"},{"count":1,"reaction":"ACUTE MYELOID LEUKAEMIA"},{"count":1,"reaction":"ACUTE RESPIRATORY DISTRESS SYNDROME"},{"count":1,"reaction":"BLOOD URINE PRESENT"},{"count":1,"reaction":"CHOLECYSTITIS"},{"count":1,"reaction":"COLITIS"},{"count":1,"reaction":"COLON CANCER METASTATIC"},{"count":1,"reaction":"HAEMATURIA"},{"count":1,"reaction":"HAEMOGLOBIN DECREASED"}],"_approvalHistory":[],"publicationCount":1284,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alkeran"],"phase":"phase_3","status":"active","brandName":"High Dose Melphalan","genericName":"High Dose Melphalan","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose melphalan is an alkylating agent that crosslinks DNA strands, causing cell death, and is used in high doses followed by stem cell rescue to treat hematologic malignancies. Used for Multiple myeloma (with autologous stem cell transplantation), Light chain amyloidosis, Waldenström macroglobulinemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}